MedCity News
MorphoSys to buy Constellation Pharma in a $1.7B bet on epigenetic cancer drugs
MorphoSys is acquiring Constellation Pharmaceuticals and its late-stage myelofibrosis drug in a deal that values the epigenetics biotech at $1.7 billion. Germany-based MorphoSys will finance the acquisition with cash from a separate $2 billion deal with drug royalty acquirer Royalty Pharma.
Shares0
MorphoSys, a biotech that has spent much of its three-decade history developing drugs that ended up at other companies via partnerships or licensing deals, is now building up its own pipeline through a $1.7 billion acquisition of Constellation Pharmaceuticals.
Constellation will bring to MorphoSys clinical-stage drugs and expertise in epigenetics, the study of turning genes on or off without altering the genetic code. That research has yielded a Phase 3 drug candidate for a rare blood cancer, as well as another compound in mid-stage testing with the potential to bring epigenetics to the
Julianne Malveaux
Dr. Julianne Malveaux is President Emerita of Bennett College for Women. She is an economist, author and commentator whose popular writings have appeared in USA Today, Black Issues in Higher Education, Ms.Magazine, Essence Magazine, The Progressive, among other publications.
Well-known for appearances on national network programs, including CNN, BET, PBS, NBC, ABC, Fox News, MSNBC, CNBC, C-SPAN and others; Malveaux is booked to offer commentary on subjects ranging from economics to women s rights and public policy. She has also hosted television and radio programs.
A committed activist and civic leader, Dr. Malveaux has held positions in women’s, civil rights, and policy organizations. Currently she serves on the boards of the Economic Policy Institute, The Recreation Wish List Committee of Washington, DC, and the Liberian Education Trust. Malveaux is also President of PUSH Excel, the educational branch of the Rainbow PUSH Coalition.
MedCity News
Congress: Pass the RAISE Act to address health disparities, advance health Equity in kidney care
As the nation continues to reckon with disparities in health, we have a real opportunity to remove barriers to proper kidney care.
Shares0
As America continues to reckon with racial injustice, we cannot let the opportunity to advance equity slip through our fingers.
For Americans of color, healthcare disparities are a constant burden: as evidenced by prevalence and morbidity in areas as diverse as Covid-19, cardiovascular disease, diabetes, asthma, and maternal health, among others.
Stemming from a legacy of slavery and structural racism, these problems will not disappear overnight. But by continuing the ongoing conversation about equity – and backing it up with real, structural change America can right these historic wrongs by expanding access to care and improving patient outcomes.
/PRNewswire/ nanoMesh™ LLC, a subsidiary of Exogenesis Corporation, announced today that it has successfully achieved the primary endpoint for the nanoMesh™.
MedCity News
Bouncing back from FDA rejection, Alkermes psychiatric drug wins approval
Alkermes antipsychotic drug Lybalvi now has FDA approval. Though the field of neuropsychiatric drugs is crowded with generic medications, Alkermes believes Lybalvi, designed to mitigate the weight gain side effect common with mood disorder drugs, could have an advantage.
Shares0
An Alkermes drug developed to offer antipsychotic effects while mitigating the weight gain associated with many depression medicines is now FDA approved as a new treatment options for patients.
The regulatory decision announced Tuesday covers use of the Alkermes drug, Lybalvi, for two indications: schizophrenia and bipolar disorder I. It follows a contentious advisory committee meeting last October, during which several physicians expressed concern about the drug’s risks in patients who are already taking opioid medications, and an FDA rejection of the drug a month later due to a manufacturing problem.